- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Robert Gabbay Explains the Development of the ADA's New CKD Guidelines
Robert Gabbay, MD, PhD, of the American Diabetes Association (ADA), discusses the development process for the section of ADA guidelines that touches on chronic kidney disease (CKD) management in patients with diabetes.
Robert Gabbay, MD, PhD, chief scientific and medical officer at the American Diabetes Association (ADA), discusses how the ADA developed section 11 of its new guidelines, which focus on the management of chronic kidney disease in patients with diabetes.
Transcript:
In recent years, the ADA has taken a comprehensive approach, working with other professional societies on guidelines in cardiovascular and renal care. Is the new section 11 an outgrowth of those conversations?
The American Diabetes Association works with a number of other societies for various sections of our standards of care. What we are very careful about doing is the makeup of our professional practice committee that is the group of individuals that develop our standards of care. And what we do is we have a broad-scale multidisciplinary, multiple-professional group—so, different types of professionals and specialists. For example, for the kidney section, we had nephrologists on the group that helped to guide these standards along with the discussion in the broader professional practice committee.
IgE Mediation in Pediatric Atopic Dermatitis, Concurrent Immune Disorders: Amy Paller, MD
August 4th 2025Amy Paller, MD, pediatric dermatologist and clinical researcher at Northwestern Medicine's Feinberg School of Medicine, discussed the potential impact of reducing immunoglobulin E (IgE) levels in pediatric patients with atopic dermatitis.
Read More
It Take a Village in Cancer Care: A Q&A With David Nguyen, MD
July 23rd 2025David Nguyen, MD, medical oncologist with Tufts Medicine and Lowell General Hospital, discusses the evolving landscape of advanced cancer treatments like chimeric antigen receptor T-cell therapy and bispecific antibodies
Read More
